Catalyst Event
D&D Pharmatech Inc (347850) · Earnings Release
From KRX Bio Technology Transfer Index (KBIOTT)
3/20/2026, 12:00:00 AM
Filed its annual audit report for FY2025 on 2026-03-20, reporting revenue of KRW 4.3 billion and an operating loss of KRW 34.0 billion; low impact estimated as a standard filing.
Korean Translation
2026년 3월 20일 2025회계연도 감사보고서를 제출하여 매출 43억 원 및 영업손실 340억 원을 기록함. 통상적인 실적 발표로 낮은 영향이 예상됨.
Related Recent Events
LigaChem Biosciences Inc (141080) · Other
Presentation of preclinical results for two next-generation BCMA ADC pipeline candidates at the American Association for Cancer Research (AACR) 2026 annual meeting scheduled
4/17/2026, 12:00:00 AM
Hanmi Pharm Co Ltd (128940) · Other
The 16th annual general shareholders' meeting is scheduled for March 31, 2026. Key agenda items include the appointment of directors, with potential for a proxy fight amid a renewed management dispute between major shareholders and current management. High impact is estimated as management disputes often lead to significant price volatility scheduled
3/31/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Other
The 20th Annual General Meeting of Shareholders including approval of financial statements and appointment of a new director scheduled
3/31/2026, 12:00:00 AM
OliX Pharmaceuticals Inc (226950) · Other
Announcement of positive preclinical results for obesity treatment OLX501A showing 84% ALK7 gene suppression in primates and plans to accelerate development expected. High efficacy in primate studies is estimated to result in a price impact of over 5%, expected.
3/24/2026, 12:00:00 AM
Hanmi Pharm Co Ltd (128940) · Other
Approval from the Ministry of Food and Drug Safety to add 'back pain' as an indication for the NSAID combination drug 'Naxozol' is expected on March 24, 2026. Low impact is estimated as this is an incremental update to an existing product scheduled
3/24/2026, 12:00:00 AM
GC Cell Corporation (144510) · Other
The 15th Annual General Meeting of Shareholders was held on March 24, 2026, where the approval of financial statements and the re-appointment of an internal director were resolved.
3/24/2026, 12:00:00 AM